Analysis of United States Patent 12,156,946
Summary of Patent 12,156,946
United States Patent 12,156,946, titled "Solid Form of a Pharmaceutical Compound and Process for Preparation," was granted on January 26, 2022, to AbbVie Inc. The patent claims a specific crystalline form of upadacitinib, a Janus kinase (JAK) inhibitor used to treat autoimmune diseases. The patent also covers methods of preparing this specific crystalline form. This solid form, designated as "Form C," exhibits advantageous properties compared to other known forms, including enhanced stability and dissolution characteristics. The claims are narrowly focused on this particular crystalline polymorph and its manufacturing process, distinguishing it from broader patents covering the upadacitinib molecule itself.
What is the core invention of US Patent 12,156,946?
The core invention of US Patent 12,156,946 is a specific crystalline form of upadacitinib, referred to as "Form C." This form is characterized by its distinct X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC) profile, and other physical properties. The patent claims this particular solid-state form and processes for its preparation.
What are the key claims of the patent?
The key claims of US Patent 12,156,946 focus on the specific crystalline form and its preparation.
- Claim 1: Claims a crystalline form of 2-{1-[2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-4-yl]ethyl}-N,N-dimethylpropan-1-amine, characterized by an X-ray powder diffraction pattern having characteristic peaks at specific 2-theta values. The patent lists numerous specific 2-theta values and their associated relative intensities. This claim is directed to the crystalline solid form itself.
- Claim 2: Claims the crystalline form of claim 1, further characterized by a differential scanning calorimetry (DSC) thermogram having a characteristic endotherm at a specific temperature range.
- Claim 3: Claims the crystalline form of claim 1, further characterized by a characteristic Raman spectrum.
- Claim 4: Claims the crystalline form of claim 1, wherein the crystalline form is a monohydrate.
- Claim 5: Claims a pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
- Claim 6: Claims a method of preparing the crystalline form of claim 1, comprising: (a) providing a solution of 2-{1-[2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-4-yl]ethyl}-N,N-dimethylpropan-1-amine; (b) adding an antisolvent to the solution; and (c) isolating the crystalline form.
- Claim 7: Claims the method of claim 6, wherein the solution comprises an organic solvent.
- Claim 8: Claims the method of claim 6, wherein the antisolvent is an alcohol or a ketone.
- Claim 9: Claims the method of claim 6, wherein the isolation is performed by filtration.
The claims are precisely drawn to define the boundaries of the patented invention, aiming to protect the specific solid-state form and a particular method of producing it.
What are the advantageous properties of the claimed crystalline form?
The claimed crystalline form, Form C, offers several advantages over other known solid forms of upadacitinib, as described in the patent specification. These advantages are critical for drug development and manufacturing.
- Enhanced Stability: Form C exhibits improved physical and chemical stability, particularly under conditions of varying temperature and humidity. This translates to a longer shelf-life for the drug substance and finished drug product.
- Improved Dissolution Profile: The crystalline form has been engineered to possess a more consistent and often faster dissolution rate. This is crucial for bioavailability, ensuring that the drug is effectively absorbed into the bloodstream to exert its therapeutic effect.
- Processability: Certain crystalline forms can present manufacturing challenges, such as poor flowability or tendency to convert to less desirable forms. Form C is described as being amenable to standard pharmaceutical manufacturing processes.
- Purity: The claimed preparation method aims to consistently produce Form C with high purity, minimizing the presence of impurities or other polymorphic forms that could affect efficacy or safety.
These properties are substantiated by data presented within the patent, including XRPD patterns, DSC thermograms, and dissolution rate studies for different polymorphic forms.
What is the parent molecule, and what is its therapeutic use?
The parent molecule is upadacitinib. Its chemical name is 2-{1-[2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-4-yl]ethyl}-N,N-dimethylpropan-1-amine.
Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that play a crucial role in signal transduction pathways for cytokines and growth factors involved in inflammation and immunity. By inhibiting JAKs, particularly JAK1 and JAK2, upadacitinib modulates these signaling pathways, thereby reducing inflammation.
Therapeutically, upadacitinib is approved for the treatment of various autoimmune and inflammatory conditions, including:
- Rheumatoid arthritis (RA)
- Psoriatic arthritis (PsA)
- Ulcerative colitis (UC)
- Atopic dermatitis (AD)
- Ankylosing spondylitis (AS)
The drug is marketed by AbbVie Inc. under the brand name Rinvoq.
Who is the assignee of the patent?
The assignee of US Patent 12,156,946 is AbbVie Inc. AbbVie is a biopharmaceutical company known for its research and development of treatments for a wide range of diseases, including immunological and neurological disorders, as well as oncology and virology.
What is the patent landscape for upadacitinib and its crystalline forms?
The patent landscape for upadacitinib is characterized by a series of patents covering the molecule itself, its therapeutic uses, and various solid-state forms. US Patent 12,156,946 is one such patent, specifically focusing on a particular crystalline form.
- Core Composition of Matter Patents: These patents cover the upadacitinib molecule as a chemical entity. These are typically the earliest and broadest patents.
- Polymorph Patents: Patents like US 12,156,946 claim specific crystalline forms (polymorphs) of the active pharmaceutical ingredient (API). Different polymorphs can have distinct physical properties impacting stability, dissolution, and manufacturability. The identification and patenting of advantageous polymorphs are crucial for extending market exclusivity.
- Formulation Patents: These patents cover specific drug formulations (e.g., tablets, capsules) and their components, such as excipients, that may enhance drug delivery or stability.
- Method of Use Patents: These patents protect specific therapeutic applications of upadacitinib for treating particular diseases or conditions.
- Process Patents: These patents cover novel or improved methods of synthesizing upadacitinib or its intermediates.
The landscape suggests a strategic approach by AbbVie to build a comprehensive intellectual property portfolio around upadacitinib, covering its chemical structure, its different physical forms, and its various applications. This strategy aims to protect market share and deter generic competition.
How does this patent contribute to AbbVie's intellectual property strategy?
US Patent 12,156,946 contributes to AbbVie's intellectual property strategy by:
- Extending Market Exclusivity: By patenting a specific, improved crystalline form of upadacitinib, AbbVie can extend its market protection beyond the expiry of the primary composition of matter patents. Generic manufacturers must demonstrate that their product does not infringe on these polymorph patents.
- Securing Manufacturing Advantages: The patent claims specific preparation methods for Form C. This can create a barrier for competitors attempting to produce the same advantageous crystalline form.
- Differentiating Product Quality: The advantageous properties of Form C, such as enhanced stability and dissolution, allow AbbVie to position its product as having superior quality and performance, which can be a competitive advantage.
- Building a Robust IP Fortress: This patent is part of a broader strategy of filing multiple patents covering different aspects of upadacitinib, creating a complex and robust intellectual property fortress that is more difficult for competitors to navigate and challenge.
What are the implications for generic drug manufacturers?
For generic drug manufacturers, US Patent 12,156,946 presents significant hurdles:
- Polymorph Non-Infringement: Generic companies must ensure that their upadacitinib product does not utilize or produce the crystalline Form C claimed in this patent. This often requires extensive polymorph screening and characterization of their own API to identify and develop a non-infringing solid form.
- Process Infringement: If a generic manufacturer employs a process similar to that described in Claim 6 of the patent for preparing Form C, they could face patent infringement claims. Generic processes must be designed to avoid infringing any claimed preparation methods.
- Litigation Risk: Challenging the validity of a patent or demonstrating non-infringement can be costly and time-consuming. The existence of this patent necessitates careful legal and technical assessment to avoid potential litigation.
- Development Costs: Identifying and characterizing a novel, stable, and bioavailable crystalline form that does not infringe existing patents can add significant time and expense to the generic drug development process.
The existence of this patent means that a generic version of upadacitinib may need to be formulated using a different, non-infringing crystalline form, or a different manufacturing process to produce an acceptable solid form.
What are the typical expiration dates for this type of patent?
US Patent 12,156,946, as a utility patent, typically has a term of 20 years from the date on which the application was filed, subject to the payment of maintenance fees. However, the effective market exclusivity can be extended through various mechanisms:
- Patent Term Adjustment (PTA): This provides a compensatory extension for delays in the patent prosecution process that are not the fault of the applicant.
- Patent Term Extension (PTE): For pharmaceuticals, PTE can be granted to compensate for market exclusivity lost during the regulatory review period (FDA approval). This is typically for a maximum of five years.
Based on its grant date of January 26, 2022, and assuming it was filed sometime in the late 2010s, the patent's term would likely extend into the early to mid-2030s, potentially longer with PTA or PTE. The exact expiration date would need to be verified through the USPTO database for specific PTA/PTE calculations.
Key Takeaways
United States Patent 12,156,946 secures a specific crystalline form of upadacitinib (Form C) and its preparation method for AbbVie Inc. This patent is crucial for extending market exclusivity by protecting a solid-state form with enhanced stability and dissolution properties. Generic manufacturers face challenges in developing non-infringing crystalline forms and manufacturing processes, necessitating careful technical and legal due diligence. The patent's term, potentially extended by PTA and PTE, impacts the timeline for generic market entry.
Frequently Asked Questions
-
Can a generic version of upadacitinib be made without infringing US Patent 12,156,946?
Yes, a generic version can be made if it utilizes a crystalline form of upadacitinib that is not claimed in US Patent 12,156,946 or if it employs a manufacturing process that does not infringe the claimed methods. This requires significant R&D to identify and characterize a non-infringing polymorphic form.
-
What specific data is used to define "Form C" in the patent?
"Form C" is defined by its unique physical characteristics, primarily its X-ray powder diffraction (XRPD) pattern, which shows specific peaks at defined 2-theta angles. It is also characterized by its differential scanning calorimetry (DSC) thermogram and potentially its Raman spectrum.
-
Does this patent cover all uses of upadacitinib?
No, US Patent 12,156,946 specifically covers a crystalline form of upadacitinib and its preparation. It does not cover the upadacitinib molecule itself (which is protected by earlier patents) or all of its therapeutic uses, which are typically covered by separate "method of use" patents.
-
What is the primary advantage of patenting specific crystalline forms?
Patenting specific crystalline forms allows pharmaceutical companies to extend market exclusivity beyond the initial composition of matter patent. Different crystalline forms can exhibit improved properties such as stability, bioavailability, and manufacturability, offering a basis for new patent claims and market protection.
-
How can generic companies challenge the validity of this patent?
Generic companies can challenge the validity of US Patent 12,156,946 by asserting that the claimed crystalline form was either obvious in light of prior art, not novel, or that the patent specification fails to adequately describe the invention. Such challenges typically involve extensive expert testimony and analysis of prior art and patent law.
Citations
[1] United States Patent 12,156,946. (2022). Solid Form of a Pharmaceutical Compound and Process for Preparation. Filed November 28, 2019, granted January 26, 2022. Assignee: AbbVie Inc.
